The new non-nucleoside reverse transcriptase inhibitors

Infections in Medicine

Volumn 13, Issue 8, 1996, Pages 715-731

  Swindells, Susan ^a,b   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Acquired immune deficiency syndrome (AIDS); Delavirdine; Human immunodeficiency virus (HIV); Nevirapine; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ANTIVIRUS AGENT; ATEVIRDINE MESYLATE; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRANSCRIPTASE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; HUMAN; REVIEW;

EID: 0029794412     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Wei X, Ghosh SK, Taylor ME, et al: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122, 1995.
2. Ho DD, Neumann AU, Perelson AS, et al: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126, 1995.
3. Meng TC, Fischl MA, Boota AM, et al: Combination therapy with ziclovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: A phase I/II study. Ann Intern Med 116:13-20, 1992.
4. Larder BA, Kemp SD, Harrigan PR, et al: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269 (5224):696-699, 1995.
5. Collier AC, Coombs RW, Fischl MA, et al: Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 119:786-793, 1993.
6. Aboulker JP, Swart AM: Preliminary analysis of the Concorde trial. Lancet 341:889-890, 1993.
7. Volberding PA, Lagakos SW, Grimnes JM, et al: The duration of zidovudine benefit in persons with asymptomatic HIV infection: Prolonged evaluation of protocol 019 of the AIDS Clinical Trial Group. JAMA 272:437-442, 1994.
8. Merluzzi VJ, Hargrave KD, Labadia M, et al: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413, 1990.
9. Pauwels R, Andries K, Desmyter J, et al: Potent and selective inhibition of HIV-1 replication by a novel series of TIBO derivatives. Nature 313:470-474, 1990.
10. Baba M, DeClerq E, Iida S, et al: Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel G-substituted acyclouridine derivatives. Antimicrob Agents Chemother 34:2358-2363, 1990.
11. Goldman ME, Nunberg JH, O'Brien JA, et al: Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A 88:6863-6867, 1991.
12. Goldman ME, O'Brien JA, Ruffing TL, et al: L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro. Antimicrob Agents Chemother 36:1019-1023, 1992.
13. Dueweke TJ, Poppe SM, Romero DL, et al: U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 5:1127-1131, 1993.
14. Baba M, DeClerq E, Tanaka H, et al: Potent and selective inhibition of human immunodeficiency virus type 1 by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A 88:2356-2360, 1991.
15. Baba M, DeClerq E, Tanaka H, et al: Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol Pharmacol 39:805-810, 1991.
16. Richman D, Rosenthal AS, Skog M, et al: BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 35:305-308, 1991.
17. Campbell TB, Young RK, Eron JJ, et al: Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atervidine (U-87201E) in combination with zidovudine or didanosine. J infect Dis 168:318-326, 1993.
18. Havlir D: Antiretroviral therapy: Update on nonnucleoside reverse transcriptase inhibitors (NNRTI). Program Abstr Intersci Conf Antimicrob Agents Chemother Oct 4-7, 1994, p 279.
19. Romero DL, Busso M, Tan CK, et al: Non-nucleoside reverse transcriptase inhibitors that potently and specifically block HIV-1 replication. Proc Natl Acad Sci U S A 88:8806, 1991.
20. Wu JC, Warren TC, Adams J, et al: A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry 30:2022-2026, 1991.
21. Richman D, Shih CK, Lowy I, et al: Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 88:11241-11245, 1991.
22. Richman DD: Loss of nevirapine activity associated with the emergence of resistance in clinical trials, in Abstracts of the Eighth International Conference on AIDS/STD World Congress, Amsterdam, July 19-24, 1992. Abstract B183.
23. DeClerq E: Chemotherapy of the acquired immunodeficiency syndrome (AIDS): Non-nucleoside inhibitors of the human immunodeficiency virus type 1 reverse transcriptase. Int J Immunopharmacol 13(suppl 1):S83-S89, 1991.
24. Havlir D, Cheeseman SH, McLaughlin M, et al: High-dose nevirapine: Safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537-545, 1995.
25. Saag MS, Emini EA, Laskin OL, et al: A short-term clinical evaluation of L697,661, a nonnucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 329:1065-1072, 1993.
26. Staszewski S, Emini E, Massari F, et al: A double-blind randomized trial for safety, clinical, efficacy, biological activity and susceptibility testing in 120 HIV positive patients treated with L,697,661, AZT and combinations of both drugs. IX International Conference on AIDS/IV STD World Congress, Berlin, June 6-11, 1993. Abstract WS-B26-4.
27. Byrnes VW, Emini EA, Staszewski, S, et al: Combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the nonnucleoside inhibitor, L,697,661. DC International Conference on AIDS/IV STD World Congress, Berlin, June 6-11, 1993. Abstract WS-A19-5.
28. Cheeseman SH, Havlir D, Mc Laughlin MM, et al: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Synd Hum Retrovirol 8:141-151, 1995.
29. Richman DD: Loss of nevirapine activity associated with the emergence of resistance in clinical trials, in Abstracts of the Eighth International Conference on AIDS/STD World Congress, Amsterdam, July 19-24, 1992. Abstract B183.
30. D'Aquila R, Hughes M, Liou SH for the NIAID AIDS Clinical Trial Group (ACTG) Protocol 241 Team: A comparative study of zidovudine, didanosine, and double-blinded nevirapine versus a combination of zidovudine and didanosine. Presented at the Second National Conference on Human Retroviruses and Related Infections; Jan 29-Feb 2, 1995; Washington, DC. Abstract 384.
31. Cheeseman SH, Murphy RL, Saag MS, et al: Safety of high dose nevirapine after 200 mg/d leadin. IX International Conference on AIDS/IV STD World Congress, Berlin, June 6-11, 1993. Abstract PO-B26-2109.
32. Saag M, Johnson V, Wei X, et al: Clinical, pharmacokinetic, and virologic results in adults treated with nevirapine (Nev) in combination with AZT/ddC, AZT/ddI or ddI alone: Final report of the BI1009 study. Program Abstr Intersci Conf Antimicrob Agents Chemother Oct 4-7, 1994, p 218.
33. Erickson DA, Mathieu E, Hattox SE, et al: Induction of hepatic cytochrome (s) P-450 in rats by nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor. FASEB J 7: A265, 1993. Abstract 1538.
34. Wu JC, Warren TC, Adams J, et al: A novel, dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a non-substrate binding site. Biochemistry 30:2022-2026, 1991.
35. Chong KT, Pagano RT, Hinshaw RR, et al: A novel BHAP, U-90152, is synergistic with 3′azido-2′3′-dideoxythymidine (AZT) and 2′3′-dideoxycytidine (ddC) against HIV-1 replication in vitro. DC International Conference on AIDS/IV STD World Congress, Berlin, June 6-11, 1993. Abstract PO-A25-0606.
36. Pagano PJ, Chong KT: In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-57875 or interferon α. J Infect Dis 171:61-67, 1995.
37. Davey RT, Chaitt DG, Freimuth WW, et al: A randomized phase I/II trial of delavirdine (U-90152S) compared to combination nucleoside therapy in HIV-1 infection. Presented at the Second National Conference on Human Retroviruses and Related Infections, Jan 29-Feb 2, 1995, Washington, DC. Abstract 267.
38. Freimuth WW, Wathen LK, Cox SR, et al: Delavirdine (DLV) in combination with zidovudine (ZVD) causes stained antiviral and immunological effects in HIV-1 infected individuals. In Program and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 28-February 1, 1996. Abstract LB8a, p 162.
39. Wathen LK, Freimuth WW, Batts DH, et al: Phenotypic and genotypic characterization of HIV-1 viral isolates from patients treated with combined AZT and delavirdine mesulate (DLV) therapy. In Program and Abstracts of HIV Drug Resistance: Third International Workshop. Kauai, Hawaii, August 2-5, 1994, p 42.
40. Freimuth WW, Chuang-Stein CJ, Greenwald CA, et al: Delavirdine (DLV) + didanosine (ddl) combination therapy has sustained surrogate marker response in advanced HIV-1 population. In Program and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC, January 28-February 1, 1996. Abstact LB8b, p163.
41. 3, who are maintained on a stable dose of AZT. Presented at First National Conference on Human Retroviruses and Related Infections; Dec 12-16, 1993; Washington DC, Abstract 564.
42. Morse GD, Fischl MA, Cox SR, et al: Effect of food on the steady-state (SS) pharmacokinetics of delavirdine mesylate (DLV) in HIV+ patients. Abstract from Interscience Conference on Antimicrobial Agents and Chemotherapy; Sept 17-20, 1995; San Francisco. Abstract 1-30.
43. Morse GD, Cox SR, DeRemer MF, et al: Zidovudine (ZDV) pharmacokinetics (PK) during an escalating, multiple-dose study of delavirdine (DLV) mesylate. Program Abstr Intersci Conf Antimicrob Agents Chemother Oct 4-7, 1994, p 132.
44. Cox SR, Della-Coletta AA, Turner SW, et al: Single-dose pharmacokinetics (PK) studies with delavirdine (DLV) mesylate: Dose proportionality and effects of food and antacid. Program Abstr Intersci Conf Antimicrob Agents Chemother Oct 4-7, 1994, p 82.
45. Borin MT, Cox SR, Chambers JH, et al: Effect of rifampin (RIF) on delavirdine (DLV) pharmacokinetics in HIV+ patients. Program Abstr Intersci Conf Antimicrob Agents Chemother Oct 4-7, 1994, p 82.
46. Borin MT, Cox SR, Driver MR, et al: Effect of rifabutin (RFB) on delavirdine (DLV) pharmacokinetics in HIV+ patients. Program Abstr Intersci Conf Antimicrob Agents Chemother, Oct 4-7, 1994, p 81.